Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)

Open to people ages 18-85

• Participants with known or newly diagnosed UC who require hospitalization for an acute moderate to severe flare
• Age 18-85
• Able to fully participate in all aspects of the trial
• Consented and able to receive first HBOT session within first 48 hours of initiation of intravenous steroids
• Agreement to not participate in another trial for the duration of the active intervention period

• Received hyperbaric oxygen therapy either as part of standard of care or through a clinical trial prior to enrollment
• Complication requiring urgent surgical intervention
• Requirement for new start of a biologic or small molecule during the hospitalization prior to randomization and/or anticipated requirement for rescue medical or surgical therapy within 48 hours of randomization
• Toxic megacolon
• Inability to receive intravenous steroids
• Historically failed or been exposed to 4 or more classes of advanced therapeutic options
• Known or suspected diagnosis of Crohn's colitis, indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, microscopic colitis or infectious colitis
• Received any investigational drug within 30 days
• Clinically significant cardiac, renal, neurological, endocrine, respiratory or hepatic impairment that increases the risk for HBOT toxicity
• Women who are pregnant or nursing
• Unwillingness to complete course of HBOT